Dick, Katherine
Schneider, John E.
Briggs, Andrew
Lecomte, Pascal
Regnier, Stephane A.
Lean, Michael
Article History
Received: 26 March 2020
Accepted: 2 May 2021
First Online: 14 May 2021
Declarations
:
: All UK Biobank participants gave informed consent for the collection and use of their data for research purposes. UK Biobank approved the use of data for this stud<i>y under Application Number 44371.</i>
: Not Applicable.
: Katherine Dick is an employee of Avalon Health Economics which received compensation from Novartis AG for this work. John Schneider is CEO and a shareholder of Avalon Health Economics which received compensation from Novartis AG for this work. Andrew Briggs is a Director and shareholder of Avalon Health Economics which received compensation from Novartis AG for this work. Pascal Lecomte is employed by, owns stock in and has stock options in Novartis Pharma AG. Stephane A. Regnier is an employee and a shareholder of Novartis Pharma AG. Michael Lean declares that he has no competing interests for this work.